On November 1, 2023 IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, reported that William Ho, CEO and co-founder, will participate in 1×1 meetings at the Truist Securities BioPharma Symposium being held Wednesday, November 8 and Thursday, November 9, 2023, in New York, NY (Press release, In8bio, NOV 1, 2023, View Source [SID1234636640]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company expects multiple preclinical and clinical data updates through year-end 2023 including at the upcoming Society for Immunology of Cancer (SITC – abstract # 637, 418), Society for Neuro-Oncology (SNO), and American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meetings.